State of the art in tumor antigen and biomarker discovery.

State of the art in tumor antigen and biomarker discovery.

Item
http://www.wikidata.org/entity/Q37132800
Applying Subtractive Hybridization Technique to Enrich and Amplify Tumor-Specific Transcripts of Esophageal Squamous Cell Carcinoma.Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies.Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.Co-delivery of human cancer-testis antigens with adjuvant in protein nanoparticles induces higher cell-mediated immune responses.Lectin-functionalized mesoporous silica nanoparticles for endoscopic detection of premalignant colonic lesions.Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature.
P2860

State of the art in tumor antigen and biomarker discovery.

Item
http://www.wikidata.org/entity/Q37132800
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
State of the art in tumor antigen and biomarker discovery.
@en
State of the art in tumor antigen and biomarker discovery.
@nl
type
label
State of the art in tumor antigen and biomarker discovery.
@en
State of the art in tumor antigen and biomarker discovery.
@nl
prefLabel
State of the art in tumor antigen and biomarker discovery.
@en
State of the art in tumor antigen and biomarker discovery.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
State of the art in tumor antigen and biomarker discovery
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932